India Targeted Therapy Drugs Market Size & Growth Rate
According to 6Wresearch internal database and industry insights, the India Targeted Therapy Drugs Market was valued at USD 604.0 million in 2025 and is projected to reach USD 920.26 million by 2032, growing at a CAGR of approximately 6.2% during 2026–2032.
India Targeted Therapy Drugs Market Highlights
| Report Metric | Details |
| Report Name | India Targeted Therapy Drugs Market |
| Market Size 2025 | USD 604.0 million |
| Market Size 2032 | USD 920.26 million |
| Absolute Growth 2025–2032 | USD 316.26 million |
| CAGR 2026–2032 | 6.2% |
| Peak Annual Growth | 8.4% in 2027 |
| Forecast Period | 2026–2032 |
| Historical Data | 2022–2025 |
| Base Year | 2025 |
| Leading Drug Class, 2025 | Kinase Inhibitors (47% share) |
| Leading Target Pathway, 2025 | VEGF/EGFR (38% share) |
| Leading Formulation Type, 2025 | Oral Tablet (35% share) |
| Leading End User, 2025 | Cancer Hospitals (34% share) |
| Fastest-Growing Drug Class | CDK Inhibitors (8.3% CAGR) |
| Fastest-Growing Target Pathway | PI3K/Akt/mTOR Pathway (8.3% CAGR) |
| Fastest-Growing Formulation Type | Capsule (7.9% CAGR) |
| Fastest-Growing End User | Oncology Clinics (7.7% CAGR) |
| Growing Sector | oncology |
| Key End Users | Cancer Hospitals, Oncology Clinics, Research Institutions |
India Targeted Therapy Drugs Market Year-wise Growth Rate and Key Drivers (2022–2032)
This graph illustrates the annual growth rates of the market from 2022 to 2032, highlighting a steady upward trajectory and projected market expansion over the forecast period.
Below, each year's estimated growth is shown next to the factor that most influenced it.
| Year | Estimated Annual Growth (%) | Market Rationale |
| 2022 | 3.8 | Demand for targeted therapy drugs remained stable, reflecting ongoing cancer treatment needs. |
| 2023 | 7.5 | The market experienced accelerated growth due to increased cancer cases and treatment adoption. |
| 2024 | 6.2 | Demand growth slowed as the National Health Mission began to improve cancer care services. |
| 2025 | 6.8 | The market rebounded with renewed interest in targeted therapies among cancer hospitals and clinics. |
| 2026 | 7.6 | Growth continued as the Central Drugs Standard Control Organization streamlined approval processes for new therapies. |
| 2027 | 8.4 | A peak in growth occurred as new therapies gained traction in oncology settings across the country. |
| 2028 | 4.1 | The market experienced a slowdown as the growth rate adjusted following the peak in the previous year. |
| 2029 | 4.8 | Demand increased again as more oncology clinics began integrating targeted therapies into their treatment regimens. |
| 2030 | 6.0 | Growth remained steady, supported by ongoing clinical trials for new therapies in major cities like Bangalore and Delhi. |
| 2031 | 5.2 | The market saw a slight slowdown as competition among suppliers intensified, impacting growth rates. |
| 2032 | 7.4 | Demand is expected to rise again as new guidelines and health initiatives promote targeted therapy usage. |
Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.
India Targeted Therapy Drugs Market Synopsis
The India Targeted Therapy Drugs Market consists of medications designed to specifically target cancer cells based on their genetic and molecular characteristics. Developed through advanced biopharmaceutical techniques, these drugs are primarily used in oncology settings. The market is growing due to over 1 million new cancer cases annually, alongside initiatives like the National Health Mission that improve cancer care services.
Market Dynamics Impact Analysis (2026–2032)
| Factor | Type | Impact | Primary Segment Affected |
| Increasing incidence of cancer cases driving demand for effective treatments | Driver | High | Kinase Inhibitors |
| Expansion of specialized cancer hospitals and clinics adopting targeted therapies | Driver | High | Cancer Hospitals |
| Growing need for innovative cancer treatments in urban areas | Opportunity | Medium | Oncology Clinics |
| Emerging research institutions focusing on targeted therapy development | Opportunity | Medium | Research Institutions |
| Regulatory hurdles in the approval process for new therapies | Restraint | High | Angiogenesis Inhibitors |
| High costs associated with targeted therapy drugs limiting accessibility | Restraint | High | IV Infusion |
| The Targeted Therapy Drugs market in India faces significant regulatory challenges | Challenge | High | Kinase Inhibitors |
| Limited awareness among healthcare providers about new therapies | Challenge | Medium | Cancer Hospitals |
Evaluation of Drivers in India Targeted Therapy Drugs Market (2026–2032)
The table below links each growth driver to the segment it affects and the evidence for it.
| Drivers | Primary Segment Affected | Why It Matters (Evidence) |
| Rising cancer incidence necessitating effective treatment options | Kinase Inhibitors | India has over 1 million new cancer cases annually, increasing demand for targeted therapies. |
| Expansion of specialized cancer treatment facilities | Cancer Hospitals | Over 500 specialized cancer centers in India are increasingly adopting targeted therapies. |
| Ongoing clinical trials for new therapies in major cities | Research Institutions | Clinical trials for targeted therapies are ongoing in cities like Bangalore and Delhi. |
| Growing patient populations in oncology clinics | Oncology Clinics | The average patient population in oncology clinics is estimated to be around 200,000 annually. |
| Support from research funding initiatives for new treatments | Angiogenesis Inhibitors | The Indian Council of Medical Research supports research on targeted therapies with various funding programs. |
The Targeted Therapy Drugs market in India is on the rise as the increasing incidence of cancer, a growing patient population, and ongoing clinical trials create a strong demand for effective treatments. With over 1 million new cancer cases reported annually, healthcare facilities are adopting targeted therapies at an accelerated pace. The presence of over 500 specialised cancer centres ensures wider access to these therapies. The average patient population in oncology clinics stands at around 200,000, driving greater procurement of these drugs. This vibrant environment is cultivating a robust market for targeted therapies.
Evaluation of Restraints in India Targeted Therapy Drugs Market
The table below lists the restraints and the evidence behind each.
| Market Restraint | Primary Segment Affected | Why It Matters (Evidence) |
| Regulatory hurdles delaying the approval of new targeted therapies | Angiogenesis Inhibitors | The Central Drugs Standard Control Organization updated guidelines in 2023, streamlining the approval process. |
| High costs of targeted therapy drugs limiting patient access | IV Infusion | The average treatment cost can be prohibitive, affecting patient affordability and access. |
| Limited awareness among healthcare providers about new treatment options | Kinase Inhibitors | Many providers are not fully informed about the latest targeted therapies available. |
| Inconsistent availability of targeted therapies across regions | Cancer Hospitals | Certain states, like Maharashtra and Tamil Nadu, report higher cancer prevalence, impacting drug distribution. |
| Competition from alternative cancer treatments affecting market share | Oncology Clinics | The presence of various treatment modalities can divert attention from targeted therapies. |
India Targeted Therapy Drugs Market Challenges
In the India Targeted Therapy Drugs Market, buyers struggle with intense competition among treatment options, leading to price wars that erode profit margins for oncology clinics. Suppliers encounter challenges in maintaining consistent quality, as compliance with ISO 9001:2015 standards is inconsistent, causing delays in drug availability for hospitals. High costs associated with targeted therapies burden buyers, with the average patient spending around 200,000 annually on these treatments, limiting access to essential care. Slow technological advancements in drug development hinder the introduction of new therapies, reducing treatment options for patients in need.
Trends in the India Targeted Therapy Drugs Market
Below mentioned are some of the trends shaping the India Targeted Therapy Drugs Market growth.
- Shift from Traditional to Targeted Cancer Therapies: Since 2021, the National Cancer Control Programme has promoted targeted therapies, increasing their adoption in treatment protocols. This shift is seen as hospitals integrate these therapies into their offerings, improving patient outcomes.
- Emergence of New Biomarkers in Cancer Treatment: In 2022, advancements in biomarker identification led to more personalized treatment options. This trend is reshaping oncology practices, as hospitals increasingly utilize targeted therapies tailored to individual patient profiles.
- Growth in Clinical Trials for Targeted Therapies: In 2023, clinical trials for new targeted therapies increased, with over 100 ongoing studies in major cities. This surge reflects the commitment to advancing cancer treatment options and improving patient care.
- Integration of Targeted Therapies into Public Health Initiatives: As of 2023, the National Health Mission emphasizes incorporating targeted therapies into public health strategies. This integration aims to improve access to advanced cancer treatments across the country.
Investment Opportunities in the India Targeted Therapy Drugs Market
Some of the investment opportunities in the India Targeted Therapy Drugs Market are mentioned below.
- Partnerships with Local Research Institutions: Now is the time to invest in collaborations with research institutions focusing on targeted therapy development. With over 1 million new cancer cases annually, such partnerships can drive innovation and market presence.
- Expansion of Oncology Clinics in Urban Areas: The growing patient population in urban oncology clinics presents an opportunity for targeted therapy suppliers. Investing in these facilities can meet the rising demand for effective cancer treatments.
- Certification for Domestic Manufacturing of Targeted Drugs: With the Department of Pharmaceuticals promoting domestic manufacturing, there is an opportunity to invest in local production facilities. This move can reduce costs and improve accessibility for patients.
- Entering the Market through Joint Ventures: Now is an ideal time for joint ventures with local firms to navigate regulatory landscapes. This strategy can facilitate quicker market entry and improve distribution networks.
Government Initiatives in the India Targeted Therapy Drugs Market
The regulatory framework governing targeted therapy drugs in India is shaped by several key measures. The Drugs and Cosmetics Act, enforced by the Drug Controller General of India, outlines the approval process for these medications. In 2021, the National Cancer Control Programme was launched to improve treatment accessibility, followed by the Ayushman Bharat scheme in 2022, which provides health insurance coverage for cancer treatments, including targeted therapies. The Central Drugs Standard Control Organization updated guidelines in 2023 to streamline the approval process for new targeted therapy drugs, making it easier for producers to bring innovations to market.
In 2023, the Indian government allocated significant funding to the National Health Mission, which emphasises the integration of targeted therapies into public health initiatives. The Ministry of Health and Family Welfare oversees this programme, aiming to enhance access to cancer care services across the country. The Department of Biotechnology also supports innovation in targeted therapies through the Biotechnology Industry Research Assistance Council scheme, which funds various research projects and initiatives.
Future Insight of the India Targeted Therapy Drugs Market
The India Targeted Therapy Drugs Market is expected to evolve by 2032, driven by the government's National Health Mission aimed at improving cancer care services. Increased funding from the Indian Council of Medical Research will support the development of new therapies. The establishment of specialised cancer centres will improve patient access to targeted treatments. Ongoing clinical trials in major cities like Bangalore and Delhi will facilitate the introduction of new therapies, broadening treatment options for oncology clinics and enhancing patient outcomes.
Market Segmentation Analysis
Each segment group is reviewed below, with the leader by share and the fastest grower by CAGR.
By Drug Class – Kinase Inhibitors Dominated, CDK Inhibitors Expected to Grow Fastest
According to Sumit Sagar, AM at 6Wresearch, Kinase Inhibitors took a 47% share of drug class in 2025, more than any other category. Kinase Inhibitors hold the largest market share in India as they are specifically designed for treating prevalent cancer types, particularly in high-incidence regions like Maharashtra. Their established role in standard treatment protocols reinforces their dominance in the targeted therapy drugs market. Over 2026–2032, CDK Inhibitors are expected to post the fastest growth, at a CAGR of 8.3%. CDK Inhibitors are experiencing rapid growth due to their crucial function in regulating cell cycle progression, which is vital for effective cancer therapies. The increasing number of clinical trials focusing on CDK Inhibitors indicates a promising future for their adoption. Suppliers should focus on enhancing the availability of CDK Inhibitors to meet the rising demand in cancer treatment.
By Target Pathway – VEGF/EGFR Dominated, PI3K/Akt/mTOR Pathway Expected to Grow Fastest
VEGF/EGFR held a 38% share of the India Targeted Therapy Drugs Market by target pathway in 2025. The VEGF/EGFR pathway leads the market as it plays a critical role in inhibiting cancer growth across various malignancies prevalent in India. Its significance is underscored by extensive research and established treatment protocols in numerous cancer hospitals nationwide. The quickest growth will come from PI3K/Akt/mTOR Pathway, forecast to expand at a CAGR of 8.3% between 2026 and 2032. The PI3K/Akt/mTOR pathway is witnessing rapid growth due to its essential role in cancer cell survival, attracting heightened research interest. The ongoing clinical trials targeting this pathway suggest a robust future demand for related therapies. Buyers should prioritise therapies that target the PI3K/Akt/mTOR pathway to remain competitive in cancer treatment advancements.
By Formulation Type – Oral Tablet Dominated, Capsule Expected to Grow Fastest
Oral Tablet accounted for a 35% market share by formulation type in 2025. Oral Tablets dominate the market share due to their convenience and ease of administration, making them a preferred choice among cancer patients. Their widespread acceptance in treatment protocols across various healthcare facilities solidifies their leading status. Capsule is projected to grow fastest, at a CAGR of 7.9% during 2026–2032. Capsules are experiencing the fastest growth as they align with patient preferences for user-friendly formulations in targeted therapies. This trend is expected to continue as more patients seek convenient and effective treatment options. Suppliers must consider expanding their capsule offerings to cater to the evolving preferences of patients.
By End User – Cancer Hospitals Dominated, Oncology Clinics Expected to Grow Fastest
With a 34% revenue share in 2025, Cancer Hospitals was the largest end user category. Cancer Hospitals are the primary end-users of targeted therapy drugs, capturing a substantial market share as they provide comprehensive treatment services for cancer patients. The extensive network of over 500 specialised cancer centres in India highlights their crucial role in this market. Oncology Clinics are set to record the highest CAGR in this split, 7.7% over 2026–2032. Oncology Clinics are rapidly adopting targeted therapies, driven by the increasing patient population and the demand for specialised cancer care. This trend is likely to persist as more clinics integrate advanced treatment options into their services. Suppliers should target oncology clinics to capitalise on the growing market for targeted therapies.
Key Attractiveness of the Report
- 10 Years of Market Numbers
- Historical Data Starting from 2022 to 2025
- Base Year 2025
- Forecast Data until 2032
- Key Performance Indicators Impacting the Market
- Major Upcoming Developments and Projects
Key Highlights of the Report:
- India Targeted Therapy Drugs Market Outlook
- Market Size of India Targeted Therapy Drugs Market, 2025
- Forecast of India Targeted Therapy Drugs Market, 2032
- Historical Data and Forecast of India Targeted Therapy Drugs Revenues & Volume for the Period 2022 - 2032F
- India Targeted Therapy Drugs Market Trend Evolution
- India Targeted Therapy Drugs Market Drivers and Challenges
- India Targeted Therapy Drugs Price Trends
- India Targeted Therapy Drugs Porter's Five Forces
- India Targeted Therapy Drugs Industry Life Cycle
- Historical Data and Forecast of India Targeted Therapy Drugs Market Revenues & Volume By Drug Class for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Drugs Market Revenues & Volume By Kinase Inhibitors for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Drugs Market Revenues & Volume By Angiogenesis Inhibitors for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Drugs Market Revenues & Volume By mTOR Inhibitors for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Drugs Market Revenues & Volume By CDK Inhibitors for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Drugs Market Revenues & Volume By Target Pathway for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Drugs Market Revenues & Volume By VEGF/EGFR for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Drugs Market Revenues & Volume By VEGFR for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Drugs Market Revenues & Volume By PI3K/Akt/mTOR Pathway for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Drugs Market Revenues & Volume By Cell Cycle Proteins for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Drugs Market Revenues & Volume By Formulation Type for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Drugs Market Revenues & Volume By Oral Tablet for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Drugs Market Revenues & Volume By IV Infusion for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Drugs Market Revenues & Volume By Capsule for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Drugs Market Revenues & Volume By Oral for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Drugs Market Revenues & Volume By End User for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Drugs Market Revenues & Volume By Cancer Hospitals for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Drugs Market Revenues & Volume By Oncology Clinics for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Drugs Market Revenues & Volume By Research Institutions for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Therapy Drugs Market Revenues & Volume By Pharmaceutical Firms for the Period 2022 - 2032F
- India Targeted Therapy Drugs Import Export Trade Statistics
- Market Opportunity Assessment By Drug Class
- Market Opportunity Assessment By Target Pathway
- Market Opportunity Assessment By Formulation Type
- Market Opportunity Assessment By End User
- India Targeted Therapy Drugs Top Companies Market Share
- India Targeted Therapy Drugs Competitive Benchmarking By Technical and Operational Parameters
- India Targeted Therapy Drugs Company Profiles
- India Targeted Therapy Drugs Key Strategic Recommendations
Market Covered
The report offers an extensive study of the following market segments.
By Drug Class
- Kinase Inhibitors
- Angiogenesis Inhibitors
- mTOR Inhibitors
- CDK Inhibitors
By Target Pathway
- VEGF/EGFR
- VEGFR
- PI3K/Akt/mTOR Pathway
- Cell Cycle Proteins
By Formulation Type
- Oral Tablet
- IV Infusion
- Capsule
- Oral
By End User
- Cancer Hospitals
- Oncology Clinics
- Research Institutions
- Pharmaceutical Firms
